PMID- 33601412
OWN - NLM
STAT- MEDLINE
DCOM- 20210830
LR  - 20240330
IS  - 1540-9538 (Electronic)
IS  - 0022-1007 (Print)
IS  - 0022-1007 (Linking)
VI  - 218
IP  - 1
DP  - 2021 Jan 4
TI  - Tumor-infiltrating dendritic cell states are conserved across solid human 
      cancers.
LID - 10.1084/jem.20200264 [doi]
LID - e20200264
AB  - Dendritic cells (DCs) contribute a small fraction of the tumor microenvironment 
      but are emerging as an essential antitumor component based on their ability to 
      foster T cell immunity and immunotherapy responses. Here, we discuss our 
      expanding view of DC heterogeneity in human tumors, as revealed with 
      meta-analysis of single-cell transcriptome profiling studies. We further examine 
      tumor-infiltrating DC states that are conserved across patients, cancer types, 
      and species and consider the fundamental and clinical relevance of these 
      findings. Finally, we provide an outlook on research opportunities to further 
      explore mechanisms governing tumor-infiltrating DC behavior and functions.
CI  - (c) 2020 Gerhard et al.
FAU - Gerhard, Genevieve M
AU  - Gerhard GM
AD  - Center for Systems Biology, Massachusetts General Hospital and Harvard Medical 
      School, Boston, MA.
FAU - Bill, Ruben
AU  - Bill R
AD  - Center for Systems Biology, Massachusetts General Hospital and Harvard Medical 
      School, Boston, MA.
FAU - Messemaker, Marius
AU  - Messemaker M
AD  - Center for Systems Biology, Massachusetts General Hospital and Harvard Medical 
      School, Boston, MA.
FAU - Klein, Allon M
AU  - Klein AM
AD  - Department of Systems Biology, Harvard Medical School, Boston, MA.
FAU - Pittet, Mikael J
AU  - Pittet MJ
AD  - Center for Systems Biology, Massachusetts General Hospital and Harvard Medical 
      School, Boston, MA.
AD  - Department of Pathology and Immunology, University of Geneva, Geneva, 
      Switzerland.
AD  - Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
LA  - eng
GR  - R01 CA218579/CA/NCI NIH HHS/United States
GR  - P01 CA240239/CA/NCI NIH HHS/United States
GR  - R01 CA206890/CA/NCI NIH HHS/United States
GR  - U01 CA224348/CA/NCI NIH HHS/United States
GR  - R01 AI084880/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Exp Med
JT  - The Journal of experimental medicine
JID - 2985109R
SB  - IM
MH  - Dendritic Cells/*immunology/pathology
MH  - Gene Expression Profiling
MH  - Humans
MH  - Neoplasms/classification/*immunology/pathology
MH  - Tumor Microenvironment/*immunology
PMC - PMC7754678
COIS- Disclosures: R. Bill reported that is wife is an employee and stockholder of CSL 
      Behring. His salary is funded by a postdoc fellowship of the Swiss National 
      Science Foundation (SNSF; P400PM_183852). M.J. Pittet reported personal fees from 
      Aileron Therapeutics, AstraZeneca, Cygnal Therapeutics, Elstar Therapeutics, KSQ 
      Therapeutics, Merck, and Siamab Therapeutics outside the submitted work. No other 
      disclosures were reported.
EDAT- 2021/02/19 06:00
MHDA- 2021/08/31 06:00
PMCR- 2021/07/04
CRDT- 2021/02/18 20:21
PHST- 2020/05/22 00:00 [received]
PHST- 2020/07/23 00:00 [revised]
PHST- 2020/10/12 00:00 [accepted]
PHST- 2021/02/18 20:21 [entrez]
PHST- 2021/02/19 06:00 [pubmed]
PHST- 2021/08/31 06:00 [medline]
PHST- 2021/07/04 00:00 [pmc-release]
AID - 211613 [pii]
AID - jem.20200264 [pii]
AID - 10.1084/jem.20200264 [doi]
PST - ppublish
SO  - J Exp Med. 2021 Jan 4;218(1):e20200264. doi: 10.1084/jem.20200264.